nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries
|
Pirenne, France |
|
|
10 |
6 |
p. e468-e476 |
artikel |
2 |
Appropriate use of sex and gender for diversity, equity, and inclusion in biomedical research
|
Bibb, Lorin A |
|
|
10 |
6 |
p. e397-e398 |
artikel |
3 |
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia
|
Curran, Emily |
|
|
10 |
6 |
p. e393-e394 |
artikel |
4 |
Celebrating blood donors amid advances in blood transfusion
|
The Lancet Haematology, |
|
|
10 |
6 |
p. e389 |
artikel |
5 |
Correction to Lancet Haematol 2023; 10: e250–60
|
|
|
|
10 |
6 |
p. e399 |
artikel |
6 |
Correction to Lancet Haematol 2023; 10: e246–47
|
|
|
|
10 |
6 |
p. e399 |
artikel |
7 |
Correction to Lancet Haematol 2023; 10: e419–32
|
|
|
|
10 |
6 |
p. e399 |
artikel |
8 |
Correction to Lancet Haematol 2023; 10: e445–57
|
|
|
|
10 |
6 |
p. e399 |
artikel |
9 |
Dealing with a changing medical landscape
|
Lucas, Tiffany L |
|
|
10 |
6 |
p. e402 |
artikel |
10 |
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial
|
Alexander, Sarah |
|
|
10 |
6 |
p. e445-e457 |
artikel |
11 |
Expanding therapeutic options for patients with primary immune thrombocytopenia
|
Lozano, Maria L |
|
|
10 |
6 |
p. e390-e391 |
artikel |
12 |
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility
|
Mills, Georgia S |
|
|
10 |
6 |
p. e458-e467 |
artikel |
13 |
Long-term sequelae after immunotherapeutic approaches in haematological malignancies—what do we know?
|
Escherich, Gabriele |
|
|
10 |
6 |
p. e395-e396 |
artikel |
14 |
Lucy Asamoah-Akuoko—sourcing blood amid varied obstacles
|
Cavanaugh, Ray |
|
|
10 |
6 |
p. e403 |
artikel |
15 |
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
|
Jabbour, Elias |
|
|
10 |
6 |
p. e433-e444 |
artikel |
16 |
Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia
|
Ghara, Niharendu |
|
|
10 |
6 |
p. e391-e393 |
artikel |
17 |
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group
|
Sato, Atsushi |
|
|
10 |
6 |
p. e419-e432 |
artikel |
18 |
Painting the place where procedures cause pain
|
Beitzke, Sabine |
|
|
10 |
6 |
p. e404-e405 |
artikel |
19 |
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
|
Liu, Xiaofan |
|
|
10 |
6 |
p. e406-e418 |
artikel |
20 |
49th annual meeting of the EBMT
|
del Pozo Martín, Yaiza |
|
|
10 |
6 |
p. e400-e401 |
artikel |